Studying the Role and Molecular Mechanisms of MAP4K3 in Sorafenib Resistance of Hepatocellular Carcinoma

Sorafenib is the first FDA-approved therapeutic drug for molecular target medication on advanced-stage hepatocellular carcinoma. It is reported that sorafenib could improve the survival of progression-free patients for 4 to 6 months; however, most of the patients developed drug resistance. Thus, it...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yi, Mo, Xiaofei, Hong, Simei, Li, Tianbao, Chen, Baozhen, Chen, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665914/
https://www.ncbi.nlm.nih.gov/pubmed/33204699
http://dx.doi.org/10.1155/2020/4965670

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665914/
https://www.ncbi.nlm.nih.gov/pubmed/33204699
http://dx.doi.org/10.1155/2020/4965670

Ejemplares similares